Payment overview · 2025
General Payments
$161.62
9 reported records · 6 companies
Healthcare provider profile · identity verified
Gerald L Parker, MD
Allopathic & Osteopathic Physicians|Family Medicine · AMORY, MS · NPI 1780690842
Verified facts
What the public records show
CMS Open Payments records show Gerald L Parker, MD received $161.62 in general payments during 2025 across 9 reported records.
Amgen Inc. accounted for 29.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.82 | 29.6% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $38.81 | 24.0% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.97 | 14.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.07 | 12.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.04 | 10.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.91 | 9.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $161.62 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $47.82 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $38.81 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
50 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 546 | 152 |
| Atorvastatin Calcium | Atorvastatin Calcium | 455 | 129 |
| Losartan Potassium | Losartan Potassium | 433 | 117 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 425 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 361 | 91 |
| Gabapentin | Gabapentin | 324 | 77 |
| Hydrochlorothiazide | Hydrochlorothiazide | 307 | 96 |
| Omeprazole | Omeprazole | 304 | 94 |
| Lisinopril | Lisinopril | 300 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 279 | 81 |
| Carvedilol | Carvedilol | 271 | 75 |
| Potassium Chloride | Potassium Chloride | 269 | 85 |
| Metformin Hcl Er | Metformin Hcl | 245 | 73 |
| Escitalopram Oxalate | Escitalopram Oxalate | 243 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 233 | 69 |
| Ezetimibe | Ezetimibe | 219 | 62 |
| Allopurinol | Allopurinol | 218 | 52 |
| Metformin Hcl | Metformin Hcl | 210 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 195 | 67 |
| Meloxicam | Meloxicam | 192 | 55 |
| Duloxetine Hcl | Duloxetine Hcl | 183 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 178 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 174 | 45 |
| Furosemide | Furosemide | 172 | 67 |
| Pregabalin | Pregabalin | 166 | 41 |
| Prednisone | Prednisone | 153 | 102 |
| Famotidine | Famotidine | 151 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 132 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 34 |
| Simvastatin | Simvastatin | 124 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 119 | 37 |
| Glipizide Er | Glipizide | 116 | 32 |
| Montelukast Sodium | Montelukast Sodium | 116 | 29 |
| Trazodone Hcl | Trazodone Hcl | 112 | 38 |
| Eliquis | Apixaban | 109 | 29 |
| Sertraline Hcl | Sertraline Hcl | 106 | 28 |
| Cefdinir | Cefdinir | 99 | 85 |
| Spironolactone | Spironolactone | 94 | 24 |
| Trulicity | Dulaglutide | 94 | 18 |
| Buspirone Hcl | Buspirone Hcl | 84 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 20 |
| Donepezil Hcl | Donepezil Hcl | 79 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 76 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 75 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 70 | 22 |
| Warfarin Sodium | Warfarin Sodium | 70 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 66 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 59 | 47 |
| Tramadol Hcl | Tramadol Hcl | 59 | 11 |
| Ozempic | Semaglutide | 57 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 17 |
| Fluconazole | Fluconazole | 55 | 32 |
| Memantine Hcl | Memantine Hcl | 55 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 54 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | 19 |
| Januvia | Sitagliptin Phosphate | 53 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 52 | suppressed |
| Mounjaro | Tirzepatide | 52 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | 14 |
| Azithromycin | Azithromycin | 50 | 44 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 17 |
| Synthroid | Levothyroxine Sodium | 50 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 30 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | suppressed |
| Xarelto | Rivaroxaban | 44 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 39 | 16 |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Glimepiride | Glimepiride | 37 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 37 | 14 |
| Jardiance | Empagliflozin | 35 | suppressed |
| Alprazolam | Alprazolam | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 27 |
| Celecoxib | Celecoxib | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Cephalexin | Cephalexin | 32 | 19 |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 32 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | 12 |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 22 |
| Ipratropium Bromide | Ipratropium Bromide | 28 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 15 |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 19 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | 11 |
| Finasteride | Finasteride | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Erythromycin | Erythromycin Base | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Nystatin | Nystatin | 17 | 11 |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 11 |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 14 |
| Diazepam | Diazepam | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $161.62 · 9 records | Amgen Inc. | BREZTRI, CAPLYTA, Cologuard Collection Kit, EVENITY, VRAYLAR, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error